Search
Search
Keeping an eye on care of the future
Dr. Khaldon Abbas is using his curiosity and passion for ophthalmology to improve patient care and outcomes for people with eye diseases and disorders.
While in university, Dr. Khaldon Abbas had a deeply moving experience as a volunteer with the Canadian Centre for Victims of Torture (CCVT) that changed the trajectory of his life and career.
The community-based organization helps victims of war and torture, and Abbas, whose family immigrated to Canada from Iraq a little more than a decade before, wanted to share his skills as a translator and tutor with newcomers.
“I came to Canada when I was 12. I had limited English, we had no family or friends here, and it was really hard to acclimate,” says Abbas. “I wanted to give back to the community and to be there for immigrant families who were facing similar challenges that my family had to deal with.”
During one shift with CCVT, Abbas was paired with a family from Syria, whose nine-year old daughter was losing her eyesight. She was living with retinal dystrophy, a degenerative disorder that can progress to complete blindness.
Witnessing the impact the eye disorder had on the young girl and her family inspired Abbas to further his own education and set a goal to become an ophthalmologist.
That was eight years ago. Since then, Abbas spent several years working as a clinical research coordinator and completed four years of medical school at the University of British Columbia.
Today, he is a clinical research fellow at the Ivey Eye Institute of St. Joseph’s Health Care London (St. Joseph’s) – a position supported through St. Joseph’s Health Care Foundation thanks to the generosity of donors.
During the next year, Abbas’ research will focus on improving patient care and outcomes for people with eye diseases and disorders.
Drs. Phil Hooper, Verena Juncal and Tom Sheidow, all retinal surgeons at Ivey Eye, are the impetus behind the fellowship and now serve as Abbas’ mentors. Through the fellowship, the trio wanted to expand their clinical research program which is heavily focused on clinical trials. Their goal was to delve into quality improvement projects and explore, among other things, patient data, referral patterns and wait times – information that could guide Ivey Eye in refining care to better understand how to improve the overall flow of patient care.
As surgeons at the largest single-site eye care centre in Canada committed to innovative care, the Ivey Eye physician leaders felt a responsibility to make this work a reality.
“We started talking about this about three years ago,” says Sheidow. “We were familiar with similar roles at other academic eye care centres and we were fortunate to have some funding, so we brought the idea to the foundation and started to craft the terms of reference,” he adds.
Abbas is the second physician in this fellowship, following in the footsteps of Dr. Amy Basilious, who is now in her second year of residency at Ivey Eye.
“Amy did an exceptional job as our inaugural fellow and we were looking for someone with similar characteristics – bright, curious, motivated, a self-starter and a passion for ophthalmology,” says Sheidow. “Khaldon has all of that and more,” he adds, referring to Abbas’ interest and background in clinical trial work.
Even before arriving in London for the fellowship, Abbas began working with his new team to generate research project ideas and shape a research plan. Among the projects he will tackle is one that will assess the effectiveness and complications of lens exchange surgeries, and another in collaboration with Basilious focused on macular hole repairs.
He will also spearhead two quality improvement studies aimed at streamlining the referral process to Ivey Eye for optometrists and enhancing education and information resources for patients with eye diseases and disorders. Through his work, Abbas is excited to build his research skills, forge new professional connections and see some of his research translated into tangible improvements in patient care.
He’s grateful to Hooper, Juncal and Sheidow, along with St. Joseph’s and the Foundation, for their vision and spirit of innovation in establishing the fellowship.
“Everyone has been extremely welcoming and supportive of me, especially my mentors and fellow co-workers” he says. “There’s a real family environment at St. Joseph’s. I feel like this is my new home away from home.”
Keith Sequeira
Keith Sequeira, MD
Associate Professor, Schulich School of Medicine and Dentistry
Implementation Science and Education
Dr. Keith Sequeira is a physiatrist at St. Joseph's Health Care London and London Health Sciences Centre and an associate professor in the Department of Physical Medicine and Rehabilitation in the Schulich School of Medicine and Dentistry at Western University. Dr. Sequeira completed his medical degree at the University of Toronto in 1994, residency training in Physical Medicine and Rehabilitation at Albany Medical Center in 1998, followed by a fellowship in Electrodiagnostic and Sports Medicine at Michigan State University.
Dr. Sequeira is the Medical Director of the Acquired Brain Injury Rehabilitation Program at Parkwood Institute and runs spasticity, EMG, brain and spinal cord injury clinics. Dr. Sequeira is the past Residency Program Director of Physical Medicine & Rehabilitation at Western, a program that he designed and initiated in 2005 and functions. He is the WSIB Champion, working on the integration of WSIB education into the medical school curriculum at Western, past director of the undergraduate the musculoskeletal curriculum within the medical school at Western, the recipient of the Dean’s Award of Excellence for Undergraduate Medical Education, and has authored numerous publications, including a 2020 article in the New England Journal of Medicine on lumbar radiculopathy.
Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia
Researchers at Lawson are studying Ambroxol - a common cough medicine in Europe - as a potential treatment for dementia linked to Parkinson’s disease.
LONDON, Ont. – Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.
Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol - a cough medicine used safely for decades in Europe - can slow dementia in people with Parkinson’s disease.
Published today in the prestigious JAMA Neurology, this 12-month clinical trial involving 55 participants with Parkinson’s disease dementia (PDD) monitored memory, psychiatric symptoms and GFAP, a blood marker linked to brain damage.
Parkinson’s disease dementia causes memory loss, confusion, hallucinations and mood changes. About half of those diagnosed with Parkinson’s develop dementia within 10 years, profoundly affecting patients, families and the health care system.
Led by Cognitive Neurologist Dr. Stephen Pasternak, the study gave one group daily Ambroxol while the other group received a placebo.
“Our goal was to change the course of Parkinson’s dementia,” says Pasternak. “This early trial offers hope and provides a strong foundation for larger studies.”
Key findings from the clinical trial include:
Ambroxol was safe, well-tolerated and reached therapeutic levels in the brain.
Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol.
Participants with high-risk GBA1 gene variants showed improved cognitive performance on Ambroxol.
A marker of brain cell damage (GFAP) increased in the placebo group but stayed stable with Ambroxol, suggesting potential brain protection.
Although Ambroxol is approved in Europe for treating respiratory conditions and has a long-standing safety record - including use at high doses and during pregnancy - it is not approved for any use in Canada or the U.S.
“Current therapies for Parkinson’s disease and dementia address symptoms but do not stop the underlying disease,” explains Pasternak. “These findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist.”
An old drug with new possibilities
Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson’s disease, GCase levels are often low. When this enzyme doesn’t work properly, waste builds up in brain cells, leading to damage.
Pasternak learned about Ambroxol during a fellowship at The Hospital for Sick Children (SickKids) in Toronto, where it was identified as a treatment for Gaucher disease - a rare genetic disorder in children caused by a deficiency of GCase. He is now applying that research to explore whether boosting GCase with Ambroxol could help protect the brain in Parkinson’s related diseases.
“This research is vital because Parkinson’s dementia profoundly affects patients and families,” says Pasternak. “If a drug like Ambroxol can help, it could offer real hope and improve lives.”
Funded by the Weston Family Foundation, this study is an important step toward developing new treatments for Parkinson’s disease and other cognitive disorders, including dementia with Lewy bodies. Pasternak and his team plan to start a follow-up clinical trial focused specifically on cognition later this year.
- 30 –
Dr. Stephen Pasternak is available for interviews on June 30.
To arrange, please contact:
Allison Hansen, Communication Consultant
St. Joseph’s Health Care London
Cell: 519-933-4272
About Lawson Research Institute: Lawson Research Institute, the health innovation arm of St. Joseph's Health Care London, is committed to making and sharing discoveries that improve lives locally and internationally. Every day, Lawson researchers work to transform imagination to innovation to patient impact. Lawson leads health-care research. Find us online at sjhc.london.on.ca/research and on social media @stjosephslondon
Largest trial ever done in hemodialysis care examines optimal dialysis temperature
More than 15,000 patients participated across 84 hemodialysis centres
LONDON, ON – Published in the Lancet, findings from a large clinical trial through Lawson Health Research Institute (Lawson), ICES Western and Western University suggest that lowering dialysis temperatures does not lead to improved patient outcomes, despite previous studies suggesting otherwise.
The standard temperature for dialysis treatments is approximately 36.5 degrees Celsius, which is similar to a human’s body temperature. But over the past several years, there have been small studies suggesting that cooler dialysis temperatures could reduce the risk of cardiovascular-related deaths and hospitalizations and better maintain blood pressures during hemodialysis treatments.
“There have been studies looking at whether a lower dialysis temperature would result in better outcomes,” says Dr. Amit Garg, Lawson Scientist, Site Director for ICES Western and Associate Dean of Clinical Research at Western’s Schulich School of Medicine & Dentistry. “The studies have been limited, especially in numbers, yet the practice of lowering the dialysis temperature has become a practice growing in popularity. Some institutions have even made this a centre-wide policy for all hemodialysis patients.”
Over the course of four years, the research team examined outcomes of both standard and cooler dialysis treatments in more than 15,000 patients. This was done across 84 of 97 hemodialysis centres in Ontario, and in terms of the number of patients, it the largest hemodialysis trial ever published worldwide.
Ten of the centres were those operated through London Health Sciences Centre (LHSC).
“We wanted to determine if lowering the dialysis temperature would help people live longer and healthier,” explains Dr. Garg, who is also a Nephrologist at LHSC. “We also measured symptoms and how people felt on the dialysis. We set out to collect high-quality evidence to make sure we are doing the right thing for patients.”
The research team examined linked healthcare data sets from ICES. The trial period included a total of 4.3 million hemodialysis treatments. Patients were randomized to receive dialysis with either the standard temperature or a lowered dialysis temperature of 0.5 degrees Celsius to 0.9 degrees Celsius below each patient’s measured pre-dialysis body temperature, with a lowest recommended temperature of 35.5 degrees Celsius.
“We did not see any benefits to patients who had the lowered temperature with no improvements to cardiovascular health. Some patients experienced discomfort from the lower dialysis temperature,” says Dr. Garg. “The results suggest we should not be adopting lower dialysis temperatures, as a centre-wide policy, and its utility in select patient care warrants scrutiny.”
The findings were presented by Dr. Garg at the American Society of Nephrology conference in Orlando, Florida on Friday Nov 4th @ 11:45 am EST.
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Western delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.
The Institute for Clinical Evaluative Sciences (ICES) is an independent, non-profit organization that uses population-based health information to produce knowledge on a broad range of health care issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting health care needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. For the latest ICES news, follow us on Twitter: @ICESOntario
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca
Last Words
Dr. Rahel Eynan is a researcher with Lawson Health Research Institute who has dedicated her life to studying the nature of suicide and those affected.
She is the lead author on a study recently published in Suicide and Life-Threatening Behavior by The American Association of Suicidology. A first of its kind in the world, this study retrospectively compared the psychosocial and clinical characteristics of people who have died by suicide and left an E-note with those who left a paper note, or no note at all.
“Suicide notes are intimate last communications left by suicide decedents to their loved ones, friends or foes,” explains Dr. Eynan. Only a minority of suicide decedents leave a suicide note, which is defined as a message expressed by a person who intends to end their life.
Typically, the notes are handwritten on paper, walls, body parts or mirrors. However, electronic suicide notes have been reported with increasing frequency including communication through email, text messages, tweets, blogs, video sharing websites, chat rooms and posts on social media networks.
This emerging phenomenon remains generally under-researched.
“The notes play an important role in forensic investigations and have evidentiary value in the courtroom. They are also considered integral to understanding suicidal behaviour as they provide a unique opportunity to examine an unsolicited account of the person’s thoughts and emotions prior to the self-destructive act,” says Dr. Eynan.
This study was embedded in the Southwestern Ontario Suicide Study (SOSS) and was conducted in collaboration with the Office of the Chief Coroner and Ontario Forensic Pathology Services and the London regional coroner office. The researchers collected data for 476 deaths by suicide that occurred between January 2012 and December 2014. Socio-demographic, psychosocial and clinical characteristics were collected with a modified version of the Manchester questionnaire used in the UK.
“Note leaving does not appear to be a random phenomenon among suicide decedents. There are common characteristics between those that do offer a final communication and in what form,” states Dr. Eynan.
They found that final communication was left by 45.8 per cent of the individuals and of those almost 75 per cent left notes that were handwritten or typed. Electronic notes were left by 17.9 per cent, usually in the form of text messages, and 7.8 per cent left a combination of paper and electronic notes, as some people left more than one. Some notes contain a just a single word while others were several pages in length.
The average age of suicide decedents is 47.2 years old and the majority are men. Death by suicide often happens after a major life transition, including those involving finances, business and employment or the dissolution of a marriage or relationship. In some cases, it is associated with a mental illness.
Those who did not leave a note were more likely to have had a diagnosed mental disorder; histories of self-harm; other physical illnesses; previous admissions to hospital or mental health services; and, been assessed for suicide behavior 3 months prior to their death.
People who left a note were significantly younger in age; more likely to be divorced or separated; less likely to be living with a partner; and, less likely to have been retired.
“Suicide decedents with fewer than two admissions to a mental health unit, including those with no history at all, were three times more likely to have left a suicide note,” explains Dr. Eynan. “Two-thirds of these people however did have contact with a primary health care provider in the month prior to their deaths. Interestingly, most were for routine and non-urgent reasons.”
Suicide notes are written for several purposes. It can be an opportunity to put affairs in order, justify or explain their suicidal action, or reduce the emotional burden of those left behind.
It can be theorized that people without a diagnosis of mental illness and fewer health care admissions may be more compelled to complete their suicide narrative and explain their motives. On the other hand, those who did not leave notes may have felt that their long-standing struggles with mental illness were well known to family and friends.
The findings point to a subgroup of younger suicide people who have less contact with mental health services, have no mental illness and yet are at risk of suicide.
“This tells us that we can be more proactive in assessing for suicidal behaviours at each interaction of help-seeking and health care.” For example, routinely giving screening questions at every appointment which assess mood and other indicators. “It could be something like a paper form or tablet in the waiting room, reducing the stigma and more easily opening up the conversation,” adds Dr. Eynan.
The general public should also be educated to take any communication by any means of suicide risk or intent as serious.
The shifting methods of communicating final good-byes that make use of newer forms of technologies could provide a window of opportunity for intervention. Social media sites and app developers could partner with researchers to develop innovative protocols and mechanisms that identify users at risk and intervene by sending the user links to crisis services or directly connecting them to an appropriate service.
Dr. Eynan is often reminded of the quote ‘whoever saves a life, saves an entire world.’ She takes the utmost care to treat each person’s story with dignity and respect.
“There was a lot of suffering shared in the notes, but the most prevalent messages were expressions of love.”
While this kind of research can be difficult, it gives her a lot of hope.
If you need help:
Canadian Mental Health Association’s Reach Out program is a 24-7 telephone hotline and internet service for individuals experiencing mental health concerns, addictions or crisis.
Reach Out can be contacted at 519-433-2023, toll free at 1-866-933-2023 or online at www.reachout247.ca.
Latest findings on gait and dementia available to public through open access
September is World Alzheimer’s Month and Saturday, September 21 was World Alzheimer’s Day.
In recognition, the Journal of Alzheimer’s Disease has published an open access, special issue that will be available to everyone for the first two weeks of publication.
Dr. Manuel Montero-Odasso, Scientist at Lawson Health Research Institute, has edited and led the special issue focusing on gait disorders and dementia.
He is world renowned for his findings on the relationship between cognition and mobility in the elderly, and gait as a predictor of frailty and dementia. He leads the Mobility, Exercise and Cognition (MEC) Team in London, comprised of top researchers in the areas of mobility, exercise and brain health.
Dr. Montero-Odasso is also a professor at Western University’s Schulich Medicine & Dentistry, geriatrician at St. Joseph’s Health Care London and London Health Sciences Centre, and Director of the Gait and Brain Lab, a part of Lawson’s Parkwood Institute Research group.
“This Journal of Alzheimer’s Disease supplemental issue showcases studies presenting the epidemiology of gait disturbances and cognitive impairment, dissecting specific associations between cognitive domains and quantitative gait parameters, and addressing with advanced neuroimaging techniques the potential mechanisms underlying the gait-cognitive interaction seen before dementia,” explains Dr. Montero-Odasso. “Also, this issue highlights how to manage mobility impairment in the cognitive impaired by using assistive devices.”
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. It is the most common cause of dementia among older adults. There are over half a million Canadians living with dementia - plus about 25,000 new cases diagnosed every year. By 2031, that number is expected to rise to 937,000, an increase of 66 per cent.
Read the Gait Disorders Special Issue with editorial from Drs. Montero-Odasso and George Perry entitled “Gait Disorders in Alzheimer’s Disease and Other Dementias: There is Something in the Way You Walk.”
Laura Graham
Laura Graham, PT, PhD
Assistant Professor, School of Physical Therapy
Neurological injury, mild traumatic brain injury
Laura Graham is an Assistant Professor and Graduate Chair of Western University’s Master of Physical Therapy Program, and an Associate Scientist with Lawson Health Research Institute. Professor Graham’s teaching focus is neurological injury/illness rehabilitation and her research interests revolve around the development of interventions for adults with persistent symptoms following concussion or other mild traumatic brain injuries (mTBI).
Professor Graham has worked as a physiotherapist at Parkwood Institute since 2011, primarily in adult brain injury rehabilitation. She has consulted with Ontario Brain Institute and WSIB Ontario on mTBI Program of Care revision, presented education of the treatment of mTBI both locally and internationally, and has taught physiotherapist instructors across Canada about concussion/mTBI rehabilitation for the National Orthopaedic Division of the Canadian Physiotherapy Association.
Professor Graham is currently helping to develop and evaluate two interventions for adults with mTBI. The first is BrainEx90, which is a circuit training-style therapy that covers self-management exercises, vision rehabilitation, vestibular rehabilitation, balance and core stability, cardiovascular training, and cognitive rehabilitation. nd the second is MyBrainPacer™ App, which is a symptom self-management tool to support people with mTBI through planning and pacing activities.
Lawson and Western researchers suggest walking and talking can be an early predictor of dementia
In a new study, researchers at Lawson Health Research Institute and Western University are demonstrating that gait, or motion testing, while simultaneously performing a cognitively demanding task can be an effective predictor of progression to dementia and eventually help with earlier diagnosis. To date, there is no definitive way for health care professionals to forecast the onset of dementia in a patient with memory complaints.
Dr. Manuel Montero-Odasso, a Lawson scientist, geriatrician at St. Joseph’s Health Care London, and associate professor in the Division of Geriatric Medicine at Western University’s Schulich School of Medicine & Dentistry, is leading the “Gait and Brain Study.” His team is assessing up to 150 seniors with mild cognitive impairment (MCI), a slight decline of memory and other mental functions which is considered a pre-dementia syndrome, in order to detect an early predictor of cognitive and mobility decline and progression to dementia.
Dr. Montero-Odasso with study participant, Roy Bratty
“Finding methods to detect dementia early is vital to our ability to slow or halt the progression of the disease,” says Dr. Montero-Odasso. The study, funded by the Canadian Institutes of Health Research, followed participants for six years and included bi-annual visits. Researchers asked participants to walk while simultaneously performing a cognitively demanding task, such as counting backwards or naming animals. Those individuals with MCI that slow down more than 20 per cent while performing a cognitively demanding task are at a higher risk of progressing to dementia.
“While walking has long been considered an automatic motor task, emerging evidence suggests cognitive function plays a key role in the control of walking, avoidance of obstacles and maintenance of navigation,” says Dr. Montero-Odasso. “We believe that gait, as a complex brain-motor task, provides a golden window of opportunity to see brain function.”
The “gait cost,” or speed at which participants completed a single task (walking) versus a dual-task, was higher in those MCI individuals with worse episodic memory and who struggle with executive functions such as attention keeping and time management.
“Our results reveal a ‘motor signature’ of cognitive impairment that can be used to predict dementia,” adds Dr. Montero-Odasso. “It is conceivable that we will be able to diagnose Alzheimer’s disease and other dementias before people even have significant memory loss. Our hope is to combine these methods with promising new medications to slow or halt the progression of MCI to dementia.”
The study, “Association of Dual-Task Gait with Incident Dementia in Mild Cognitive Impairment”, was published in the journal, JAMA NEUROLOGY.
Members of the study’s research team, from left to right: Korbin Blue, Research Assistant (Co-op Student); Yanina Sarquis-Adamson, Lab Research Assistant; Frederico Faria, Post-Doctoral Fellow; Dr. Montero Odasso, Director, Gait and Brain Lab; research participant; Alanna Black, Lab Research Coordinator; Stephanie Cullen, Research Assistant (Undergraduate Student); and, Navena Lingum, Research Assistant (Master Student).
Lawson celebrates Canada 150
Canada’s 150th anniversary of Confederation is an opportunity to celebrate the impact of health research over the last 150 years. In recognition, Lawson has launched a Canada 150 website (www.lawsonresearch.ca/canada150) to celebrate our past, our present and to look forward to how Lawson research can shape the future of health care.
Lawson’s Canada 150 website will be updated through the rest of the year with new content, including your feedback and ideas about the future of health research. We’re asking “What does the next 150 years hold for health research and innovation in Canada?” You can provide your input here or send us your ideas by tweeting us. We’ll be sharing your feedback on the Canada 150 website and social media throughout the year.
On July 1, Lawson will also be appearing alongside our hospital and foundation partners in a special insert of the London Free Press. Additionally, if you are celebrating Canada 150 at London’s Sesquifest you can view Lawson’s Canada 150 banner in the Explore Tent on Talbot Street.
Lawson cyclotron to produce new imaging agent that may better locate prostate cancer
Lawson Health Research Institute is the first in Canada to enter a sublicense agreement with The Centre for Probe Development and Commercialization (CPDC) to produce PSMA-1007, a new imaging agent that could help improve the detection of prostate cancer.
The radiopharmaceutical tracer can locate and bind to prostate specific membrane antigen (PSMA) – a protein on the surface of prostate cancer cells. This imaging agent makes the prostate cancer cells visible with PET/CT (positron emission tomography/computed tomography) imaging.
Dr. Glenn Bauman, a Radiation Oncologist at the London Regional Cancer Program at London Health Sciences Centre and Scientist with Lawson, has been involved in a number of research developments in PSMA PET/CT.
“Until now, a PET imaging agent called 18F-DCFPyL, was commonly used in research. More recently, we've been looking at a PET radiopharmaceutical called PSMA-1007 that may give us clearer pictures in the pelvis and the area of the prostate,” says Dr. Bauman, who is also a Professor of Oncology and Medical Biophysics at Western University’s Schulich School of Medicine and Dentistry.
Dr. Michael Kovacs, Director of the Lawson Cyclotron & PET Radiochemistry Facility at St. Joseph’s Health Care London, says the license means London will have a local supply of PSMA-1007 that is “more or less a magic bullet for prostate cancer cells.”
Radiopharmaceuticals decay quickly after production and so there is a need to produce them locally. Lawson’s cyclotron, which is housed at St. Joseph’s, is one of fewer than roughly two dozen facilities in Canada and delivers products to the GTA, Windsor and London.
“The cyclotron is a type of particle accelerator where we can accelerate particles called protons to high energy and fire them into a target that makes radioisotopes every day,” Dr. Kovacs explains. “The raw radioisotope is taken to the lab to synthesize PET radiopharmaceuticals, including PSMA imaging agents, before going through quality control.”
“Being able to produce PSMA-1007 locally is exciting, as outsourcing comes with logistical challenges if a production run fails or transportation fails,” explains says Dr. Bauman. “Having our own means of production is a real advantage to us as we conduct our research.”
CPDC, which holds the rights to produce PSMA-1007 in Canada, is already running a clinical trial in hopes of having it available in clinical settings. They expect to have study results in two to three years.
Early studies show the clearer images from PSMA-1007 may have the biggest impact in patients with a recurrence of prostate cancer who have already had treatment. The return of cancer can be very small and difficult to detect with conventional methods. In many of those cases, studies are finding a rise in PSMA levels can be an early signal of the cancer’s return, allowing for earlier diagnosis with PSMA PET.
Looking forward, PSMA-1007 has the potential to be used as a theranostic agent where by the isotope is used deliver radiation treatment directly to the cancer, but this application is likely many years away.
This is the part two of a three-part series on PSMA PET imaging research. Check out part one and three.